Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Tuesday

Key Points

• Black Diamond Therapeutics (BDTX) is expected to announce its Q2 2025 earnings on August 5th, projecting a loss of ($0.26) per share.
• The stock of Black Diamond Therapeutics opened at $2.93, with a market cap of $166.61 million and a fifty-two week high of $6.75.
• Raymond James Financial has upgraded BDTX to an "outperform" rating with a price target of $11.00, while the consensus price target from analysts is $12.80.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect Black Diamond Therapeutics to post earnings of ($0.26) per share for the quarter.

Black Diamond Therapeutics Stock Performance

Shares of BDTX stock traded down $0.07 during mid-day trading on Friday, hitting $2.59. 708,420 shares of the stock were exchanged, compared to its average volume of 2,069,090. The stock's fifty day simple moving average is $2.57 and its two-hundred day simple moving average is $2.13. Black Diamond Therapeutics has a 12-month low of $1.20 and a 12-month high of $6.75. The stock has a market capitalization of $147.28 million, a price-to-earnings ratio of 43.17 and a beta of 2.71.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on BDTX shares. Wall Street Zen raised Black Diamond Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Raymond James Financial raised shares of Black Diamond Therapeutics to an "outperform" rating and set a $11.00 target price for the company in a report on Tuesday, July 1st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $12.80.

Institutional Trading of Black Diamond Therapeutics

A hedge fund recently bought a new stake in Black Diamond Therapeutics stock. AQR Capital Management LLC bought a new position in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The fund bought 54,122 shares of the company's stock, valued at approximately $84,000. AQR Capital Management LLC owned 0.10% of Black Diamond Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 95.47% of the company's stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.